European Journal of Haematology最新文献

{"title":"Cytokine expression in pediatric patients with immune thrombocytopenia (ITP) in different phases of disease","authors":"Neeti Luke, Kristyn Pierce, Kirsty Hillier","doi":"10.1111/ejh.14262","DOIUrl":"10.1111/ejh.14262","url":null,"abstract":"","PeriodicalId":11955,"journal":{"name":"European Journal of Haematology","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141456076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evans syndrome: Disease awareness and clinical management in a nation-wide ITP-NET survey","authors":"Bruno Fattizzo,&nbsp;Valentina Carrai,&nbsp;Monica Crugnola,&nbsp;Erminia Baldacci,&nbsp;Marta Bellini,&nbsp;Costanza Bosi,&nbsp;Elisa Buzzatti,&nbsp;Domenica Caramazza,&nbsp;Giuseppe Carli,&nbsp;Monica Carpenedo,&nbsp;Cristina Clissa,&nbsp;Cristina Danesin,&nbsp;Maria Rosaria De Paolis,&nbsp;Juri Alessandro Giannotta,&nbsp;Vanessa Innao,&nbsp;Monia Marchetti,&nbsp;Uros Markovic,&nbsp;Alessandro Morotti,&nbsp;Mariasanta Napolitano,&nbsp;Andrea Patriarca,&nbsp;Loredana Pettine,&nbsp;Antonella Poloni,&nbsp;Elena Rivolti,&nbsp;Elena Rossi,&nbsp;Teresa Maria Santeremo,&nbsp;Cristina Santoro,&nbsp;Maria Elena Zannier,&nbsp;Francesco Zaja,&nbsp;Silvia Cantoni,&nbsp;Francesca Palandri,&nbsp;Valerio De Stefano","doi":"10.1111/ejh.14256","DOIUrl":"10.1111/ejh.14256","url":null,"abstract":"<p>Evans syndrome (ES) is rare and mostly treated on a “case-by-case” basis and no guidelines are available. With the aim of assessing disease awareness and current management of adult ES, a structured survey was administered to 64 clinicians from 50 Italian participating centers. Clinicians had to be involved in the management of autoimmune cytopenias and were enrolled into the ITP-NET initiative. The survey included domains on epidemiology, diagnosis, and therapy of ES and was designed to capture current practice and suggested work-up and management. Thirty clinicians who had followed a median of 5 patients (1–45)/15 years responded. The combination of AIHA plus ITP was more common than the ITP/AIHA with neutropenia (<i>p</i> &lt; .001) and 25% of patients had an associated condition, including lymphoproliferative syndromes, autoimmune diseases, or primary immunodeficiencies. The agreement of clinicians for each diagnostic test is depicted (i.e., 100% for blood count and DAT; only 40% for anti-platelets and anti-neutrophils; 77% for bone marrow evaluation). Most clinicians reported that ES requires a specific approach compared to isolated autoimmune cytopenias, due to either a more complex pathogenesis and a higher risk of relapse and thrombotic and infectious complications. The heterogeneity of treatment choices among different physicians suggests the need for broader harmonization.</p>","PeriodicalId":11955,"journal":{"name":"European Journal of Haematology","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ejh.14256","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141510812","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letermovir as secondary prophylaxis of cytomegalovirus infection after allogeneic hematopoietic cell transplantation: A single center experience","authors":"Nihar Desai,&nbsp;Ivan Pasic,&nbsp;Arjun D. Law,&nbsp;Wilson Lam,&nbsp;Armin Gerbitz,&nbsp;Auro Viswabandya,&nbsp;Dennis D. Kim,&nbsp;Rajat Kumar,&nbsp;Jonas Mattsson,&nbsp;Igor Novitzky-Basso,&nbsp;Fotios V. Michelis","doi":"10.1111/ejh.14258","DOIUrl":"10.1111/ejh.14258","url":null,"abstract":"<p>Letermovir, a novel anti-cytomegalovirus (CMV) agent acts by inhibiting the viral terminase complex and is approved for primary prophylaxis in CMV seropositive patients post allogeneic hematopoietic cell transplantation (HCT). The favorable efficacy and safety profile make it an attractive option for use as secondary prophylaxis in patients at high-risk for CMV reactivation. In this study, we report the efficacy and safety of letermovir secondary prophylaxis after at least one treated episode of CMV reactivation in a cohort of 39 high-risk patients. Thirty two (82%) patients received anti-thymocyte globulin (ATG), 27 (69%) received a combination of ATG and post-transplant cyclophosphamide for graft-versus-host disease (GVHD) prophylaxis. Twenty one patients (54%) received CMV seronegative grafts. In addition, 18 (46%) patients had HLA mismatched unrelated or haploidentical donors while 18 (46%) had active GVHD requiring immunosuppression at the time of commencing secondary prophylaxis. Letermovir was initiated at a median of 47 days (range, 41–56) after HCT and was administered for a median duration of 77 days (range, 46–90). A single breakthrough CMV reactivation was noted in this high-risk cohort. Four additional episodes of CMV reactivation occurred at a median of 28 days (range, 23–59 days) after discontinuation of secondary prophylaxis. The drug was well tolerated and 77% of the cohort completed the planned duration of secondary prophylaxis. None of the patients discontinued treatment due to treatment-related adverse effects. In conclusion, letermovir is effective and well tolerated and may be considered for secondary prophylaxis in patients at high risk for CMV reactivation. Prospective studies are required to validate these findings.</p>","PeriodicalId":11955,"journal":{"name":"European Journal of Haematology","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141510811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Plain language summary on “Interim analyses of the multinational real-world prospective cohort HEM-POWR study evaluating the effectiveness and safety of damoctocog alfa pegol in patients with hemophilia A”","authors":"","doi":"10.1111/ejh.14244","DOIUrl":"10.1111/ejh.14244","url":null,"abstract":"<p>Hemophilia A is a genetic disorder caused by severe or partial deficiency of factor VIII, an essential protein that forms blood clots. People with hemophilia can bleed during day-to-day activities, mostly occurring in joints. Controlling bleeding after injury or surgery is also challenging. Treatments, such as damoctocog alfa pegol, involve infusing factor VIII products into a vein to help blood clot, prevent (prophylaxis) or stop bleeding. Damoctocog alfa pegol has been studied in clinical trials of severe hemophilia A, but studies in normal clinical settings are needed as they better represent real-world patients. In a recent publication in the <i>European Journal of Hematology</i>, researchers studied the effectiveness and safety of damoctocog alfa pegol in a normal clinical setting (HEM-POWR). The primary focus was how treatment affects the number of bleeds a person has in a year, including joint bleeds. Unfavorable treatment reactions (adverse events) were also recorded; these describe how safe the treatment is. The HEM-POWR study found that people had fewer bleeds, including joint bleeds, on damoctocog alfa pegol compared to previous treatments. No new adverse events were reported. This research shows that damoctocog alfa pegol treatment is effective and safe in people with mild/moderate and severe hemophilia.</p>","PeriodicalId":11955,"journal":{"name":"European Journal of Haematology","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ejh.14244","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141510813","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A post hoc analysis of PROTECT VIII Kids assessing long-term efficacy and safety of damoctocog alfa pegol in adolescents with severe haemophilia A","authors":"","doi":"10.1111/ejh.14226","DOIUrl":"10.1111/ejh.14226","url":null,"abstract":"","PeriodicalId":11955,"journal":{"name":"European Journal of Haematology","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141426533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retrospective study on pomalidomide-PACE as a salvage regimen in aggressive relapsed and refractory multiple myeloma","authors":"Deniz Gezer,&nbsp;Melanie Schmitt Nogueira,&nbsp;Martin Kirschner,&nbsp;Tim H. Brümmendorf,&nbsp;Carsten Müller-Tidow,&nbsp;Hartmut Goldschmidt,&nbsp;Marc S. Raab,&nbsp;Nicola Giesen","doi":"10.1111/ejh.14254","DOIUrl":"10.1111/ejh.14254","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>Despite major advances in treatment options for multiple myeloma (MM), patients refractory to the main drug classes and those with aggressive, especially extramedullary disease, still face a dismal outcome. For these patients, effective therapeutic options are urgently warranted.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>In this retrospective study, we report on the safety and efficacy of the intensive combination regimen of pomalidomide plus cisplatin, doxorubicin, cyclophosphamide, and etoposide (Pom-PACE) in patients with relapsed refractory MM (RRMM) or plasma cell leukemia (PCL). A study population of 20 consecutive patients treated with Pom-PACE at two academic centers was included for analysis. All patients had to have a confirmed relapse according to International Myeloma Working Group criteria and adequate organ function prior to the start of therapy. Data were collected by reviewing medical charts. Exploratory analyses were performed with regard to efficacy and safety.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Patients were heavily pretreated with a median number of four prior therapies (range: 1–10). All patients were exposed to immunomodulators, proteasome inhibitors, and alkylating agents, 80% were double-class refractory, 40% were triple-class refractory. Extramedullary MM or PCL were present in 15 patients (75%). Overall response rate (ORR) was 68%, with 31% achieving at least a very good partial response. Responses were achieved rapidly with an ORR of 64% after one cycle. Median progression-free survival was 8.9 months (0.92–not reached [NR]) and median overall survival was 11.8 months (3–40.6). Pom-PACE was associated with significant toxicity. All evaluable patients experienced Grade 4 hematological toxicity. However, no treatment related mortality was observed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Pomalidomide-PACE was able to induce rapid responses in heavily pretreated, aggressive RRMM with a manageable toxicity profile and therefore offers an effective salvage regimen and a potential bridging strategy to further treatment options such as chimeric antigen receptor T-cell therapy.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11955,"journal":{"name":"European Journal of Haematology","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ejh.14254","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141426534","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Childhood autoimmune hemolytic anemia: A scoping review","authors":"Caseng Zhang,&nbsp;Danielle Charland,&nbsp;Katie O'Hearn,&nbsp;MacGregor Steele,&nbsp;Robert J. Klaassen,&nbsp;Matthew Speckert","doi":"10.1111/ejh.14253","DOIUrl":"10.1111/ejh.14253","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and objective</h3>\u0000 \u0000 <p>Autoimmune hemolytic anemia (AIHA) is a rare but important cause of morbidity in pediatric hematology patients. Given its rarity, there is little high-quality evidence on which to base the investigation and management of pediatric AIHA. This scoping review aims to summarize the current evidence and highlight key gaps to inform future studies.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This review searched MEDLINE and the Cochrane CENTRAL Trials Register from 2000 to November 03, 2023. Experimental and observational studies reporting AIHA diagnostic criteria, laboratory workup, or treatment/management in populations with at least 20% of patients ≤18 years were included.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Forty-three studies were included, with no randomized controlled trials identified. AIHA diagnostic criteria, diagnostic tests, and treatments were highly variable. First-line treatment approaches include corticosteroids, intravenous immunoglobulin, or both. Approaches to AIHA resistance to first-line therapy were widely variable between studies, but most commonly included rituximab and/or cyclosporine.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>We identify a heterogenous group of observational studies into this complex, immune-mediated disorder. Standardized definitions and classifications are needed to guide collaborative efforts needed to study this rare disease. The work done by the CEREVANCE group provides an important paradigm for future studies.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11955,"journal":{"name":"European Journal of Haematology","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ejh.14253","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141418474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intensive salvage chemotherapy with VDTPACE or mCBAD followed by hematopoietic stem-cell support for refractory/relapsed multiple myeloma","authors":"Carolina Perrone Marques,&nbsp;Danielle Ovigli,&nbsp;Mariana Nassif Kerbauy,&nbsp;Ana Carolina de Almeida Silveira,&nbsp;Ricardo Helman,&nbsp;Cinthya Correa da Silva,&nbsp;Andreza Alice Feitosa Ribeiro,&nbsp;Nelson Hamerschlak,&nbsp;Leonardo Javier Arcuri","doi":"10.1111/ejh.14257","DOIUrl":"10.1111/ejh.14257","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Triple- and quad-refractory multiple myeloma patients usually have an aggressive course and a poor prognosis. Available therapeutic options are scarce.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The objective of the current study was to evaluate responses and toxicities of VDTPACE or mCBAD with hematopoietic stem-cell support as a bridge to subsequent therapies in patients with refractory/relapsed multiple myeloma.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Thirteen patients were included (11 mCBAD, 2 VDTPACE), and 21 cycles of chemotherapy with hematopoietic stem-cell support were delivered. Mean number of previous therapies was 4.8. Stem cells were infused on a median day 9.9 after chemotherapy. Mean time to neutrophil recovery was 18.2 days in patients receiving the first cycle and 15.9 following subsequent cycles. Before therapy, most patients were in PD (77%), PR (15%), or VGPR (8%). Following treatment, the best responses achieved were PR (46%), VGPR (46%), and CR (8%). Median overall and progression-free survivals were 17 and 9 months. There has been no case of non-relapse mortality. In the 21 cycles, the main complications were infectious.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Intensive chemotherapy can decrease disease burden in patients with relapsed/refractory MM, and stem-cell support can successfully decrease toxicities and treatment-related mortality associated with these regimens and may be a good bridging option.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11955,"journal":{"name":"European Journal of Haematology","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141418475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Racial disparities in the incidence and survival outcomes in diffuse large B-cell lymphoma in adolescents and young adults","authors":"Mustafa Wasifuddin,&nbsp;Nosakhare Paul Ilerhunmwuwa,&nbsp;Henry Becerra,&nbsp;Narek Hakobyan,&nbsp;Neharika Shrestha,&nbsp;Ifeanyi Nnamdi Uche,&nbsp;Htet Lin,&nbsp;Hesham Abowali,&nbsp;Jin Zheng,&nbsp;Ruchi Yadav,&nbsp;Akriti Pokhrel,&nbsp;Ladan Enayati,&nbsp;Mitchell Hare,&nbsp;Rohan Hehr,&nbsp;Khrystyna Kozii,&nbsp;Bulat Gibadullin,&nbsp;Boris Avezbakiyev,&nbsp;Jen-Chin Wang","doi":"10.1111/ejh.14255","DOIUrl":"10.1111/ejh.14255","url":null,"abstract":"<p>Diffuse large B-cell Lymphoma (DLBCL) is an aggressive subtype of non-Hodgkin lymphoma (NHL). The disease generally occurs in older patients. Although at a lower prevalence, the disease also occurs in the adolescent and young adult group (AYA). There is paucity of data in the literature on racial and ethnic disparities in the incidence and survival outcomes of DLBCL in the AYA group. The objective of our study is to demonstrate the disparities in these outcomes. Utilizing SEER, we obtained data on patient demographics, incidence, and survival from 2000 to 2020. We observed statistically significant reduced incidence of DLBCL in all racial groups, except the non-Hispanic Asian and Pacific Islander group (NHAPI). The non-Hispanic Black group (NHB) had one of the lowest survival despite showing the largest decrease in incidence in DLBCL. The differences in the survival could be secondary to socioeconomic factors, however other reasons need to be explored. The increased incidence among the NHAPI group mirrors that of large population-based studies in East Asian countries, however, underlying reasons have not been elucidated.</p>","PeriodicalId":11955,"journal":{"name":"European Journal of Haematology","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141418476","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of cytomegalovirus (CMV) seroconversion pre-allogeneic hematopoietic cell transplantation on posttransplant outcomes","authors":"Ayman Sayyed,&nbsp;Leeann Wilson,&nbsp;Vered Stavi,&nbsp;Shiyi Chen,&nbsp;Carol Chen,&nbsp;Jonas Mattsson,&nbsp;Jeffrey H. Lipton,&nbsp;Dennis D. Kim,&nbsp;Auro Viswabandya,&nbsp;Rajat Kumar,&nbsp;Wilson Lam,&nbsp;Arjun D. Law,&nbsp;Armin Gerbitz,&nbsp;Ivan Pasic,&nbsp;Igor Novitzky-Basso,&nbsp;Tony Mazzulli,&nbsp;Fotios V. Michelis","doi":"10.1111/ejh.14251","DOIUrl":"10.1111/ejh.14251","url":null,"abstract":"<p>Cytomegalovirus (CMV) reactivation post-allogeneic hematopoietic cell transplantation (post-alloHCT) increases morbidity and mortality. We sought to determine the frequency of CMV seroconversion in patients pre-alloHCT and to investigate the impact on posttransplant outcomes. We retrospectively investigated 752 adult patients who underwent alloHCT at our center from January 2015 to February 2020 before the adoption of letermovir prophylaxis. CMV serology was assessed at consult and pretransplant. The cohort was divided into four groups based on pretransplant CMV seroconversion: negative to positive (Group 1), positive to negative (Group 2), consistently negative (Group 3), and consistently positive (Group 4). Eighty-nine patients (12%) had seroconverted from negative to positive, 17 (2%) from positive to negative, 151 (20%) were consistently seronegative, and 495 (66%) were consistently seropositive pretransplant. For the four CMV serostatus groups, cumulative incidence of CMV reactivation at 6 months posttransplant was 4.5%, 47.1%, 6.6%, and 76.6% for Groups 1, 2, 3, and 4, respectively (<i>p</i> &lt; .0001). No differences between groups were seen regarding Grade III–IV acute graft-versus-host disease (GVHD) (<i>p</i> = .91), moderate/severe chronic GVHD (<i>p</i> = .41), or graft failure (<i>p</i> = .28). On multivariable analysis, there was no impact of CMV serostatus group on overall survival (<i>p</i> = .67), cumulative incidence of relapse (<i>p</i> = .83) or non-relapse mortality. alloHCT patients who demonstrate CMV seroconversion pretransplant from negative to positive have a very low risk of CMV reactivation posttransplant. The observed seroconversion may be due to passive CMV immunity acquired through blood products. Quantitative CMV immunoglobulin G/immunoglobulin M pretransplant may help differentiate between true seroconversion and passively transmitted CMV immunoglobulin.</p>","PeriodicalId":11955,"journal":{"name":"European Journal of Haematology","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141330596","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}